GYNECOLOGIC CANCERS

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy in ongoing clinical trials.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ovarian cancer, regardless of HRD status.

Premal Thaker, MD, MS, discusses important implications and takeaways of the phase 1/2 OVATION study of IMMN-1 in addition to chemotherapy for the treatment of newly diagnosed epithelial ovarian cancer.

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

The FDA granted fast track designation to PHST001 for the treatment of advanced ovarian cancer.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for underserved women globally.

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable vulvar cancer.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.

Final analysis of KEYNOTE-A18 showed that pembrolizumab plus concurrent chemoradiation showed sustained PFS/OS benefits in high-risk locally advanced cervical cancer, establishing a new standard of care.

The FIRST/ENGOT-OV44 trial found dostarlimab plus platinum-chemo and niraparib maintenance modestly improved PFS (20.6 vs 19.2 months) in advanced ovarian cancer, with expected safety.

Toon Van Gorp, MD, PhD, discusses the rationale behind and the findings from the phase 3 MIRASOL trial of mirvetuximab soravtansine in patients with folate receptor α–positive, platinum-resistant ovarian cancer.

Patients with BRCA-altered uterine leiomyosarcoma treated with PARP inhibitors demonstrated encouraging outcomes.

Oral selinexor as maintenance therapy extended progression-free survival in patients with TP53 wild-type advanced or recurrent endometrial cancer.

The combination of pembrolizumab and lenvatinib led to encouraging clinical activity in patients with platinum-resistant high-grade serous ovarian cancer.

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.

The Wee1 inhibitor adavosertib shows activity in recurrent uterine serous carcinoma, but the drug’s tolerability remains a challenge.

Dual checkpoint inhibitors led to longer overall survival in patients with high-risk endometrial cancer who displayed inactivating PPP2R1A mutations vs patients with wild-type PPP2R1A.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer.

The combination of relacorilant and nab-paclitaxel improved progression-free and overall survival in patients with platinum-resistant ovarian cancer.